Opinion & analysis

GSK And Pfizer Assemble Consumer Healthcare Leadership Team As JV Closes

GlaxoSmithKline PLC and Pfizer Inc. have closed their consumer health joint venture to create the “global leader in OTC products.” Operating under the GSK Consumer Healthcare name, the joint venture – announced in December last year – has around a 7.3% share of the global consumer health market, well ahead of the next competitor, Johnson & Johnson, at 4.1%. Under the leadership of Brian McNamara, the new company has begun to assemble a management team that combines talent from both GSK and Pfizer. Who’s on the dream team, and what’s on the horizon for this new superpower?

GSK And Pfizer Assemble Consumer Healthcare Leadership Team As JV Closes

Unilever Seeks End To Litigation Over St. Ives Scrub, Plaintiffs’ ‘Fake Medical Condition’

Accenture Prescribes A New Data Management Future For Medtechs

US FDA’s Rush Following Novartis’ Delay Suggests Strong Displeasure With Handling Of Zolgensma Data Manipulation

Eudamed – A Moving Target But On Track For March 2020 Partial Go-Live

Transforming Pharmaceutical R&D with Data

‘Project Orbis’ Oncology Pilot Eventually Will Target ‘Major Impact’ Applications

The Oncology Burden Of Proof: Learning From The PD-1 Market

GSK Woes Raise Big Pharma R&D Question

Repositioning Market Access: A Function Fit For Purpose In A New Era Of Costly Cures

Gene Therapy Investment At All Time High, Commercialization Challenges Noted

Novartis Swaps Two AveXis Executives For One Following Zolgensma Data Manipulation

GE Healthcare’s New Value Proposition: The Strategic Language Of Software

Annuity Payment Model For Cures May Get Test Drive In Massachusetts

Bayer’s Consumer Chief Initiates Turnaround Plan In Bid To Return Troubled Business To Growth